{"id":"NCT04564742","sponsor":"AstraZeneca","briefTitle":"Dapagliflozin Effects on Cardiometabolic Outcomes in Patients With an Acute Heart Attack.","officialTitle":"A Registry-based, Randomised, Double-blind, Placebo-Controlled Cardiovascular Outcomes Trial to Evaluate the Effect of Dapagliflozin on Cardiometabolic Outcomes in Patients Without Diabetes With Acute Myocardial Infarction at Increased Risk for Subsequent Development of Heart Failure","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-12-22","primaryCompletion":"2023-07-05","completion":"2023-07-05","firstPosted":"2020-09-25","resultsPosted":"2025-03-07","lastUpdate":"2025-03-07"},"enrollment":4017,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Acute Myocardial Infarction","Heart Failure"],"interventions":[{"type":"DRUG","name":"Dapagliflozin","otherNames":["Forxiga TM","Farxiga TM"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Dapagliflozin","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study will evaluate the effect of dapagliflozin versus placebo, given once daily in addition to Standard of Care (SoC) therapies for patients with myocardial infarction (MI), for hospitalisation for heart failure (HHF), cardiovascular (CV) death, and other cardiometabolic outcomes.","primaryOutcome":{"measure":"Analysis of the Hierarchical Primary Composite Endpoint (Full Analysis Set)","timeFrame":"29 months","effectByArm":[{"arm":"Dapa 10 mg","deltaMin":1990,"sd":null},{"arm":"Placebo","deltaMin":1970,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":7},"locations":{"siteCount":103,"countries":["Sweden","United Kingdom"]},"refs":{"pmids":["38320489","37648579"],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D169DC00001&amp;attachmentIdentifier=6a26fd8c-8a16-4e88-be06-fe8f77ed02d1&amp;fileName=D169DC00001_Final_Protocol_Redacted.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D169DC00001&amp;attachmentIdentifier=e44ba4b4-00be-45a8-b7a0-d42b1e24a19d&amp;fileName=D169DC00001_Statistical_Analysis_Plan_Redacted.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D169DC00001&amp;attachmentIdentifier=b1e72f98-98f3-46d8-9ff9-cb04417bbf85&amp;fileName=D169DC00001_CSR_Synopsis_Redacted.pdf&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":449,"n":2019},"commonTop":[]}}